Artelo Biosciences(NASDAQ) ARTL

Artelo develops medicines for people with cancer, pain, and stress disorders. Its treatments aim to help those with appetite loss or chronic inflammation. The company’s work targets patients who need new options when current therapies fall short.

Lab Bench to Bedside: Artelo’s Main Offerings

• ART27.13 (Cancer Anorexia): Synthetic drug in trials for cancer-related appetite loss; targets patients with severe weight loss.
• ART26.12 (Pain and Cancer): Inhibitor for nerve pain and cancer; being tested for chemotherapy-induced nerve damage, prostate and breast cancer, and post-traumatic stress disorder (PTSD).
• ART12.11 (Inflammation and PTSD): Synthetic cannabidiol-based treatment in development for pain, inflammation, and post-traumatic stress disorder (PTSD); aims to help those with trauma-related symptoms or chronic inflammation.
• Research Collaborations: Joint studies with academic partners, including Trinity College Dublin, to advance drug development.
• Digital Asset Treasury: Holds Solana (SOL) digital assets as part of its treasury strategy; not related to core drug development.

Growth Spurts and Side Quests

• Formed research partnership with Trinity College Dublin for cancer cachexia studies.
• Raised $900,000 via convertible notes in May 2025 and $1.425 million in private placement in June 2025.
• Allocated approximately $9.475 million from the August 2025 private placement to Solana (SOL) purchases as part of its Digital Asset Treasury strategy.

What Makes Artelo Stand Out

Artelo focuses on the endocannabinoid system, a network in the body that helps regulate appetite, pain, and mood. The company combines in-house research with academic partnerships to develop new drugs. Its use of digital assets as a treasury reserve is unusual for a biotech firm.

Five Things You Need to Know

• Revenue was $0 in QQ2 2025, unchanged from QQ2 2024 and QQ2 2023.
• Net loss was $-3 million in QQ2 2025, unchanged from QQ2 2024.
• Cash and cash equivalents were $2.1 million as of June 30, 2025.
• Working capital deficit was $3.5 million as of June 30, 2025.
• Operating expenses rose to $5.5 million for the six months ended June 30, 2025, up $0.4 million from prior year.

Bottom Line

Artelo remains a pre-revenue biotech focused on new drug development for unmet medical needs. The company faces ongoing financial challenges and relies on external funding to continue operations.